Abstracts tagged "autoantibodies and human leukocyte antigens (HLA)"

Abstract Number: 1675 • 2017 ACR/ARHP Annual Meeting
SLE Comprises Four Immune-Phenotypes, Which Differ Regarding HLA-DRB1 and Clinical Associations
Lina Marcela Diaz Gallo¹, Emeli Lundström¹, Vilija Oke¹, Kerstin Elvin², Yee Ling Wu³, Johanna Gustafsson¹, Andreas Jönsen⁴, Dag Leonard⁵, Agneta Zickert⁶, Gunnel Nordmark⁷, Anders A. Bengtsson⁴, Johanna K Sandling⁷, Lars Rönnblom⁸, Iva Gunnarsson¹, CHACK-YUNG Yu⁹, Leonid Padyukov¹⁰ and Elisabet Svenungsson¹⁰, ¹Department of Medicine, Rheumatology Unit, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Dept. of Clinical Immunology and Transfusion Medicine, Unit of Clinical Immunology, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁴Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁵Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ⁸Medical Sciences, Rheumatology clinic, Uppsala, Sweden, ⁹Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH, ¹⁰Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: SLE is a remarkably heterogeneous disease including diverging clinical symptoms, autoantibodies and genetic susceptibility. Hitherto unrecognized patterns may define sub-phenotypes with different pathogenesis and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].